Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets (Q36856455)

16 August 2017

1 reference

title

Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets (English)

1 reference

16 August 2017

Panagiotis A Konstantinopoulos

series ordinal

1

1 reference

PubMed ID

17585331

16 August 2017

Michalis V Karamouzis

series ordinal

2

1 reference

PubMed ID

17585331

16 August 2017

Athanasios G Papavassiliou

series ordinal

3

1 reference

16 August 2017

1 July 2007

1 reference

Nature Reviews Drug Discovery

16 August 2017

1 reference

16 August 2017

6

1 reference

16 August 2017

7

1 reference

16 August 2017

541-555

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2221

16 August 2017

0 references

cites work

Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.

1 reference

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

21 January 2018

1 reference

Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins

21 January 2018

1 reference

G proteins: transducers of receptor-generated signals

21 January 2018

1 reference

Mechanism of the receptor-catalyzed activation of heterotrimeric G proteins

31 March 2020

1 reference

Small GTP-binding proteins

31 March 2020

1 reference

Rho GTPases in cell biology

31 March 2020

1 reference

Targeting Rab GTPases to distinct membrane compartments

31 March 2020

1 reference

Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors

31 March 2020

1 reference

The small GTPase Ran: interpreting the signs

31 March 2020

1 reference

ARF proteins: roles in membrane traffic and beyond

31 March 2020

1 reference

Small GTPases take the stage

31 March 2020

1 reference

GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors

31 March 2020

1 reference

GDIs: central regulatory molecules in Rho GTPase activation

31 March 2020

1 reference

31 March 2020

Transforming G proteins

1 reference

Ras, PI(3)K and mTOR signalling controls tumour cell growth

31 March 2020

1 reference

Targeting RAS signalling pathways in cancer therapy

31 March 2020

1 reference

Strategies to overcome resistance to targeted protein kinase inhibitors

31 March 2020

1 reference

31 March 2020

RHO-GTPases and cancer

1 reference

Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma

31 March 2020

1 reference

Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas

31 March 2020

1 reference

Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking

31 March 2020

1 reference

RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast

31 March 2020

1 reference

Influencing cellular transformation by modulating the rates of GTP hydrolysis by Cdc42

31 March 2020

1 reference

Specific contributions of the small GTPases Rho, Rac, and Cdc42 to Dbl transformation

31 March 2020

1 reference

The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers

31 March 2020

1 reference

The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production

31 March 2020

1 reference

Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues.

31 March 2020

1 reference

Requirement for Arf6 in breast cancer invasive activities

31 March 2020

1 reference

Familial cancer associated with a polymorphism in ARLTS1

31 March 2020

1 reference

Protein prenylation: molecular mechanisms and functional consequences

31 March 2020

1 reference

Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity

31 March 2020

1 reference

31 March 2020

CaaX converting enzymes

1 reference

All ras proteins are polyisoprenylated but only some are palmitoylated

31 March 2020

1 reference

Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI

31 March 2020

1 reference

31 March 2020

Isoprenylated proteins

1 reference

Structure of the human ADP-ribosylation factor 1 complexed with GDP

31 March 2020

1 reference

The tuberous sclerosis complex

31 March 2020

1 reference

RhoGDIs revisited: novel roles in Rho regulation

31 March 2020

1 reference

Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes

31 March 2020

1 reference

Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with Ezrin/Radixin/Moesin proteins

31 March 2020

1 reference

Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia

31 March 2020

1 reference

The Dbl homology domain of BCR is not a simple spacer in P210BCR-ABL of the Philadelphia chromosome

31 March 2020

1 reference

Tiam1 mutations in human renal-cell carcinomas

31 March 2020

1 reference

p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3.

31 March 2020

1 reference

Human RhoGAP domain-containing proteins: structure, function and evolutionary relationships

31 March 2020

1 reference

Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity

31 March 2020

1 reference

Changes in gene expression during progression of ovarian carcinoma.

31 March 2020

1 reference

Rab proteins and endocytic trafficking: potential targets for therapeutic intervention

31 March 2020

1 reference

Arf GAPs: multifunctional proteins that regulate membrane traffic and actin remodelling

31 March 2020

1 reference

Statins and cancer prevention

31 March 2020

1 reference

Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.

31 March 2020

1 reference

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

31 March 2020

1 reference

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

31 March 2020

1 reference

Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase

31 March 2020

1 reference

The role of statins in cancer therapy

31 March 2020

1 reference

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

31 March 2020

1 reference

Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.

31 March 2020

1 reference

Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates

31 March 2020

1 reference

Alendronate disturbs vesicular trafficking in osteoclasts

31 March 2020

1 reference

Emerging anti-cancer molecular mechanisms of aminobisphosphonates

31 March 2020

1 reference

Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo

31 March 2020

1 reference

Lipid posttranslational modifications. Farnesyl transferase inhibitors

31 March 2020

1 reference

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

31 March 2020

1 reference

Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli

31 March 2020

1 reference

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

31 March 2020

1 reference

Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB

31 March 2020

1 reference

Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice

31 March 2020

1 reference

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

31 March 2020

1 reference

Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K

31 March 2020

1 reference

Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors

31 March 2020

1 reference

Development of farnesyl transferase inhibitors: a review

31 March 2020

1 reference

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

31 March 2020

1 reference

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

31 March 2020

1 reference

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study

31 March 2020

1 reference

Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies

31 March 2020

1 reference

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

31 March 2020

1 reference

Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.

31 March 2020

1 reference

Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells.

31 March 2020

1 reference

Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors

31 March 2020

1 reference

Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes

31 March 2020

1 reference

Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation

31 March 2020

1 reference

Post-prenylation-processing enzymes as new targets in oncogenesis

31 March 2020

1 reference

Non-peptidic, non-prenylic inhibitors of the prenyl protein-specific protease Rce1

31 March 2020

1 reference

Selective inhibition of ras-transformed cell growth by a novel fatty acid-based chloromethyl ketone designed to target Ras endoprotease

31 March 2020

1 reference

Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues

31 March 2020

1 reference

Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate

31 March 2020

1 reference

A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells.

31 March 2020

1 reference

Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases

31 March 2020

1 reference

Isoprenylcysteine carboxyl methyltransferase activity modulates endothelial cell apoptosis

31 March 2020

1 reference

Ras signalling on the endoplasmic reticulum and the Golgi

31 March 2020

1 reference

Quantitative structure-activity relationship (QSAR) of indoloacetamides as inhibitors of human isoprenylcysteine carboxyl methyltransferase

31 March 2020

1 reference

Hydrophilic anilinogeranyl diphosphate prenyl analogues are Ras function inhibitors.

31 March 2020

1 reference

Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells

31 March 2020

1 reference

Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis.

31 March 2020

1 reference

Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents

31 March 2020

1 reference

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

31 March 2020

1 reference

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

31 March 2020

1 reference

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

31 March 2020

1 reference

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

31 March 2020

1 reference

Farnesyltransferase inhibitors reverse taxane resistance

31 March 2020

1 reference

Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression.

31 March 2020

1 reference

Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines

31 March 2020

1 reference

RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53.

31 March 2020

1 reference

Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro

31 March 2020

1 reference

Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid

31 March 2020

1 reference

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

31 March 2020

1 reference

Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth

31 March 2020

1 reference

Radiation sensitization by inhibition of activated Ras.

31 March 2020

1 reference

Farnesyltransferase inhibitors as radiation sensitizers

31 March 2020

1 reference

A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer

31 March 2020

1 reference

Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities

31 March 2020

1 reference

Pharmacology. Hitting the hot spots of cell signaling cascades

31 March 2020

1 reference

Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery

31 March 2020

1 reference

Dual specificity of the interfacial inhibitor brefeldin a for arf proteins and sec7 domains

31 March 2020

1 reference

Rational design and characterization of a Rac GTPase-specific small molecule inhibitor

31 March 2020

1 reference

Identification of the first Rho-GEF inhibitor, TRIPalpha, which targets the RhoA-specific GEF domain of Trio

31 March 2020

1 reference

Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization

31 March 2020

1 reference

Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.

31 March 2020

1 reference

Glucosylation of Rho proteins by Clostridium difficile toxin B.

31 March 2020

1 reference

Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.

31 March 2020

1 reference

Rho GDP dissociation inhibitors as potential targets for anticancer treatment

31 March 2020

1 reference

A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity

31 March 2020

1 reference

A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma

31 March 2020

1 reference

Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma

31 March 2020

1 reference

A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2221

1 reference

16 August 2017

1 reference

PubMed ID

17585331